Date: 2016-07-01
Type of information: Production agreement
Compound: fimaporfin - disulfonated tetraphenyl chlorin (TPCS2a) (Amphinex™)
Company: PCI Biotech (Norway) Curida (Norway)
Therapeutic area: Cancer - Oncology - Rare diseases
Type agreement: production manufacturing
Action mechanism:
Disease:
Details: * On July 1, 2016, Curida has entered into a manufacturing agreement with PCI Biotech. Curida will manufacture Amphinex™, the lead product candidate from PCI Biotech. Amphinex is currently undergoing international clinical trials for bile duct cancer. Curida is located in Elverum, Norway and offers contract manufacturing, development and laboratory services, primarily for large and small companies in the pharmaceutical sector. Curida has GMP and ISO 13485 certified facilities and builds on more than 40 years of experience from pharmaceutical manufacturing. Curida also has offices at Oslo Cancer Cluster Incubator, where they are co-located with PCI Biotech and several other biotech and pharmaceutical companies.
Financial terms:
Latest news:
